Lithium Carbonate description, usages, side effects, indications, overdosage, supplying and lots more!

Menu
Search

Lithium Carbonate

Sun Pharmaceutical Industries Limited

Lithium Carbonate Tablets USP


FULL PRESCRIBING INFORMATION: CONTENTS*




FULL PRESCRIBING INFORMATION

WARNING


Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels. Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see DOSAGE AND ADMINISTRATION).

LITHIUM CARBONATE DESCRIPTION





Inactive Ingredients:







23

CLINICAL PHARMACOLOGY


LITHIUM CARBONATE INDICATIONS AND USAGE






LITHIUM CARBONATE CONTRAINDICATIONS


WARNINGS










see DOSAGE AND ADMINISTRATION

PRECAUTIONS

General


see DOSAGE AND ADMINISTRATION





Information for the patients




Drug interactions


Combined use of haloperidol and lithium.









Non-steroidal anti-inflammatory drugs (NSAIDS)

Pregnancy, Teratogenic Effects



WARNINGS 

Nursing Mothers


Usage in Children


LITHIUM CARBONATE ADVERSE REACTIONS


Lithium toxicity











Neuromuscular



Central Nervous System



Cardiovascular



Neurological



Gastrointestinal



Genitourinary



Dermatologic



Autonomic Nervous System



Thyroid Abnormalities

3 4See PRECAUTIONS

EEG Changes



EKG Changes



Miscellaneous



Miscellaneous reactions unrelated to dosage are:



OVERDOSAGE


ADVERSE REACTIONS

Treatment



LITHIUM CARBONATE DOSAGE AND ADMINISTRATION


Acute Mania



Long-term Control





N.B.

HOW SUPPLIED


Lithium Carbonate Tablets USP








Store and Dispense:



Caraco Pharmaceutical Laboratories, Ltd.



Sun Pharmaceutical Ind. Ltd.




PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


NDC 62756-430-88
Lithium Carbonate Tablets USP
300 mg
Rx only
100 TABLETS
Sun Pharmaceutical Industries Ltd.

Lithium Carbonate

Lithium Carbonate

Lithium Carbonate TABLET

Product Information

Product Type Human prescription drug label Item Code (Source) NDC:62756-430
Route of Administration ORAL DEA Schedule

Active Ingredient/Active Moiety

Ingredient Name Basis of Strength Strength
LITHIUM CARBONATE LITHIUM CATION 300 mg

Inactive Ingredients

Ingredient Name Strength
cellulose, microcrystalline
POVIDONE K30
SODIUM LAURYL SULFATE
SODIUM STARCH GLYCOLATE TYPE A POTATO
SILICON DIOXIDE
CALCIUM STEARATE

Product Characteristics

Color Size Imprint Code Shape
WHITE (white to off-white) 10 mm 430 ROUND

Packaging

# Item Code Package Description Marketing Start Date Marketing End Date
1 NDC:62756-430-83 30 in 1 BOTTLE
2 NDC:62756-430-88 100 in 1 BOTTLE
3 NDC:62756-430-08 100 in 1 BOTTLE
4 NDC:62756-430-18 1000 in 1 BOTTLE

Marketing Information

Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA091027 2010-07-08


PLEASE, BE CAREFUL!
Be sure to consult your doctor before taking any medication!
Copyright © 2014. drugs-library.com. All rights reserved. Information on drugs-library.com is provided for educational purposes only and is not to be used for medical advice, diagnosis or treatment.
Support info@drugs-library.com.